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background: The applicability and validity of the new American College of Cardiology and American Heart Association (ACC/AHA) 
guidelines for cholesterol management remain undetermined in Asians.
Methods: Using data from the Korean National Health and Nutrition Examination Survey of 2008 to 2012 (n=18,573), we compared the 
estimated number of statin candidates under the ACC/AHA and the Third Adult Treatment Panel (ATP-III) guidelines, and extrapolated 
the results to 19.0 million Koreans of 40 to 75 years. Using external population (n=63,329) of 2003 National Health Examination, we 
determined clinical effects of concordant and discordant recommendations on major cardiovascular events (cardiovascular death, 
myocardial infarction, or stroke) and validated each risk function.
Results: Among 19.0 million adults, compared to the ATP-III guidelines, the new guideline would increase the number of statin candidates 
from 3.5 million (18.6%) to 6.7 million (35.1%). This increase would be prominent in primary prevention (3.1 million to 5.9 million) than in 
secondary prevention (0.4 million to 0.8 million). The percentage of statin candidates would more largely increase among older adults (60-
75 years; 29.8% to 74.9%) than among younger adults (40-59 years; 15.6% to 19.8%) and increase among men (27.5% to 45.4%) than 
among women (14.6% to 26.8%). In external validation cohort, compared to adults who were neither recommended by the two guidelines, 
those who were both recommended and those who were recommended by ACC/AHA but not ATP-III guidelines had a significantly higher 
adjusted risk of major cardiovascular events (HR, 1.27; 95% CI, 1.09-1.47; P=0.002 and HR 1.15; 95% CI 1.03-1.28; P=0.02, respectively). 
However, adults who were recommended by ATP-III but not ACC/AHA guidelines did not have an increased risk (HR 0.87; 95% CI 0.61-
1.26; P=0.47). Both risk functions overestimated future cardiovascular events.
conclusion:  In Korean population, the new cholesterol guidelines would substantially increase the number of adults who would be eligible 
for statin therapy and would recommend statin therapy for more adults who would have higher cardiovascular events.
